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Introduction
Somatic structural variations in the genome - referred to 
by cytogeneticists as translocations, inversions, duplica-
tions and insertions - can be powerful events in tumor 
evolution because they can create fusion genes. Fusion 
genes are formed when part of one gene is juxtaposed to 
another by a structural rearrangement, creating a hybrid 
transcript, or sometimes simply inserting a novel promo-
ter upstream of a gene. These can be very powerful 
oncogenic mutations, not only increasing expression of a 
protein but also changing its activity, subcellular localiza-
tion or binding specificity [1,2]. Such fusion genes are 
also clinically important, because some can predict 
outcome and determine management, and some may be 
targets for therapy [1]. For example, the BCR-ABL fusion 
gene defines a group of leukemias and is the target of 
treatment with the kinase inhibitor Glivec.
In stark contrast to leukemias, lymphomas and 
sarcomas, in which many important oncogenes have 
been identified at translocation breaks, we have a poor 
understanding of how structural variations contribute to 
carcinogenesis in common epithelial tumors [1,2]. 
Although we have relatively good knowledge of which 
genes can be point-mutated, amplified or deleted in these 
cancers, the sheer number and complexity of their 
genome rearrangements has made it difficult to identify 
genes at chromosome breakpoints [2]. We have known 
for several years that recurrent gene fusions are found in 
common epithelial cancers, following the discovery of 
the TMPRSS2-ERG and related fusions in prostate cancer 
[3] and EML4-ALK in lung cancer [4]. However, these 
fusions were discovered by essentially one-off methods 
and it remains to be seen whether these are isolated 
examples or the tip of an iceberg.
Stephens et al. [5] recently presented the first large-
scale survey of somatically acquired structural variation 
in the genomes of cancers, with the explicit goal of 
discovering genes disrupted and fused at chromosome 
breakpoints. The authors [5] used massively parallel 
paired end sequencing to find genome rearrangements in 
24 breast cancers - 9 of which were from immortal cell 
lines and 15 from primary tumors. Although these data 
pertain to breast cancer, we think many of the findings 
will also be relevant to other common cancers, and 
certainly they are consistent with a preceding pilot study 
of two lung cancer cell lines [6]. The Stephens et al. [5] 
study revealed that structural variants contribute 
significantly to the mutational burden of many breast 
cancers, but also that genes are often fused or otherwise 
disrupted by mechanisms we have, so far, not appreciated.
Massively parallel paired end sequencing
Massively parallel sequencing techniques generate very 
large numbers of sequence reads, but the reads are 
generally much shorter than in traditional sequencing, 
typically only tens of base pairs. To use these short 
sequence ‘tags’ efficiently to find structural rearrange-
ments, ‘paired end read’ strategies have been developed 
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(also known as ‘mate pair’ and ‘end sequence profiling’ 
strategies; Figure 1) [6]. The genome is broken into DNA 
fragments of selected size, for example 500 base pairs 
(bp) [5], and a short sequence, for example 37 bp, is read 
from each end of each DNA fragment to give paired 
sequences. Most of the fragments are normal, and their 
paired reads map back to the reference genome about 
500 bp apart and in the correct orientation. Structural 
variants are discovered when read-pairs map 
unexpectedly, for example to two different chromosomes 
(translocation), too far apart (deletion), or in the wrong 
orientation (tandem duplication or inversion) (Figure 1). 
Considerable bioinformatic processing is required to 
interpret the huge volume of sequence data, but millions 
of paired reads are pruned down to a hundred or so 
structural variants per tumor, most of which can be 
confirmed by PCR.
Stephens et al. [5] estimate that 50% of structural 
variations were detected in their study. This may seem 
like a low figure but, as the authors showed, it was 
sufficient to identify hundreds of structural variants and 
tens of fusion genes. The main reason for missing 
structural variants was that the amount of sequencing 
was not enough to sample all rearrangements. Also, 
breakpoints flanked by repeats may have been missed 
because reads from repetitive regions are currently 
discarded. We expect the proportion of structural 
variants detected to increase in the future as more 
sequencing reads are generated, the reads used are 
longer, and bioinformatic analysis is refined.
Rearrangements in breast cancers are more 
numerous than expected
There were many more structural variants than most in 
the field would have anticipated [5]. For cell lines, the 
median number of rearrangements per sample was 101 
and ranged from 58 to 245. For the tumors, the median 
was 38 and ranged from 1 to 231. Approximately 85% 
were intrachromosomal and less than 2 Mb [5], which 
explains why earlier molecular cytogenetic approaches, 
such as spectral karyotyping, array comparative genomic 
hybridization (CGH) and array painting [7], under esti-
mated the number of rearrangements. These aberrations 
would not have been visible in metaphase chromosomes 
and many were copy-number neutral or too small to have 
shown up in most array CGH experiments.
Many fusion genes were predicted and several 
were expressed
Many of the structural changes that Stephens et al. [5] 
found juxtaposed the coding regions of two genes. An 
important observation, extending earlier studies [2,7,8], 
was that some breast cancers can express several fused 
genes. Stephens et al. [5] showed that 21 novel fusion 
genes were expressed and in frame so potentially 
produced a functional fusion protein. Allowing for the 
estimated 50% detection rate, this would equate to two 
functional fusion genes per case. Most of the fusion genes 
were of unknown function but several involved known or 
likely cancer genes, such as ETV6, which is a known 
target of translocations and encodes a member of the 
oncogenic Ets transcription factor family, and EHF, 
which also encodes an Ets family member. Some genes 
seemed to be rearranged in several of the 24 samples but 
no recurrent gene fusions were identified by fluorescence 
in situ hybridization (FISH) or RT-PCR in a larger second 
set of tumors [5]. This may simply be a reflection of the 
heterogeneity of breast cancer - the samples used were 
chosen to represent a range of different tumor subtypes - 
or it may be that aberrant expression of an important 3’ 
gene can be driven by several different 5’ fusion transcript 
partners, as happens, for example, to the Ets-related gene 
ERG in prostate cancers.
Figure 1. Mapping structural variants using the paired end read 
strategy. (a) A region of genome containing a translocation junction 
between two different chromosomes (red and blue). (b) The entire 
genome is fragmented, and fragments of a desired size, typically 
500 bp, are selected. (c) The ends of the fragments are sequenced 
for a small fraction of the fragment length, typically 35 bp (black 
arrows). The Stephens et al. [5] study used 500 bp fragments and 
37 bp sequencing reads but other combinations are possible. For 
variations, see [2]. (d) The paired sequence tags are mapped back to 
the reference genome. Most pairs map back about 500 bp from each 
other on the same chromosome, but (e) the read pair spanning the 
translocation breakpoint maps back to two different chromosomes in 
the reference genome.
(a) A region with a translocation junction
(b) The whole genome is fragmented and fragments of 
     a given size selected
(c) Sequence is generated from the ends of each fragment
(d) Read pairs are aligned to the reference genome
(e) Most pairs map normally but structural variants map 
      unexpectedly
Newman and Edwards Genome Medicine 2010, 2:19 
http://genomemedicine.com/content/2/3/19
Page 2 of 4
Unanticipated classes of structural variation
An unexpected finding [5] was a number of somatically 
acquired tandem duplications, a kind of structural change 
that has rarely been detected until recently but is interesting 
because it can lead to gene fusion [9]. A tandem duplication 
occurs when a small region from 3 kb to greater than 1 Mb 
is duplicated, usually in a head-to-tail orientation. Some 
tumors showed a distinctly higher number of tandem 
duplications than the others, which led the authors [5] to 
suggest that they were generated by a specific repair defect. 
The BRCA1 and BRCA2 mutant tumors had fewer tandem 
duplications than average, so the aberrant mechanism was 
probably not related to these pathways.
The second surprising finding [5] was that many small 
tandem duplications, inversions and deletions were 
entirely within genes. In many cases this affected the exon 
structure at the transcript level and novel isoforms were 
observed. Some of these rearrangements were in putative 
oncogenes, such as the transcription-factor-encoding gene 
RUNX1, so it is plausible that oncogenic activation could 
have occurred by removing or reshuffling exons that 
encode a repressive protein domain. Well-characterized 
tumor suppressor genes such as the retinoblastoma gene 
RB also had internal rearrangements and it is possible 
these genes were inactivated through frame shift in the 
transcript or by removing important protein domains.
Two questions arise from these observations [5]: firstly, 
whether the roles of genes such as RUNX1 and RB have 
been underestimated in breast cancer, because these 
kinds of mutation would not be detected by Sanger 
sequencing studies on individual coding exons; and 
secondly, whether there are numerous small rearrange-
ments of this kind in other, karyotypically normal, cancers.
Drivers and passengers?
It is remarkable how many mutations, whether sequence-
level, epigenetic or structural, are now being discovered in 
cancer genomes [5,10,11]. Many are probably ‘passenger’ 
mutations, that is, random mutational noise, but some must 
be selected, ‘driver’ events and, as the number and variety of 
known mutations increases, estimates for the number of 
‘driving’ mutations in cancer are tending to increase [2,12].
The problem of distinguishing driver and passenger 
mutations is as acute for structural mutations as it is for 
point mutations [10-13]. Stephens et al. [5] estimate that 
approximately 2% of genome rearrangements of the types 
they found would generate an in-frame fusion gene by 
chance. They observed 1.6%, which suggests that the 
majority of gene fusions, like the majority of point 
mutations, are not selected events.
Conclusions
The Stephens et al. [5] study is the first indication that 
genome-wide structural analysis of a relatively large 
number of samples, including primary tumors, is already 
an achievable goal. More importantly, it illustrates that 
such studies are worthwhile as they can create a large 
yield of new candidate oncogenes and tumor suppressor 
genes.
Clearly, the next step is to find genes or gene families 
that are recurrently fused or rearranged in a subset of 
tumors. Thanks to the methodologies and bioinformatic 
tools already validated by pilot studies [5,6] we can expect 
large surveys of several cancer types to appear within 2 or 
3 years. This will allow us to address the question of 
recurrence and move on to establish the clinical relevance 
and potential for targeted intervention.
For the time being, massively parallel paired end 
sequencing will remain a research tool, but the basic cost 
of an analysis like that of Stephens et al. [5] is already 
down to a few thousands of euros per case, so it is 
conceivable that we will see it used in the clinic in the not 
too distant future. Indeed, while this article was in press, 
Velculescu and colleagues [14] announced a possible 
clinical application, using paired end reads to find a 
structural ‘fingerprint’ of a tumor that could be detected 
in the patient’s serum and so used to monitor 
progression.
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